Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity
Holbrook K, Sagiv-Barfi I, Sarwish R et al.
Key Points:
Effect of ibrutinib on NK cells following exposure to rituximab-coated lymphoma cells and HER2+ breast cancer cell lines.
Findings: Ibrutinib inhibited both rituximab- and trastuzumab-induced NK cell cytokine secretion in dose-dependent manner.
Implications:
- Use of ibrutinib inhibits FcR-stimulated NK cell function (in vitro), specifically ADCC.
View the original abstract on the ASH website.
